idarubicin has been researched along with Brill-Symmers Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
1 trial(s) available for idarubicin and Brill-Symmers Disease
| Article | Year |
|---|---|
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
1 other study(ies) available for idarubicin and Brill-Symmers Disease
| Article | Year |
|---|---|
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |